



STATE MEDICAID DUR BOARD MEETING
 THURSDAY, July 10, 2014
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 125



MINUTES

Board Members Present:

Tony Dalpiaz, PharmD.
 Jay Aldus, DDS
 Michael Symond, M.D.
 Keith Tolman, M.D.

Jennifer Brinton, MD
 Susan Siegfried, M.D.
 Mr. Kumar Shah
 Kyle Jones, M.D.

Board Members Excused:

George Hamblin, PharmD

Mark Balk, PharmD.

Dept. of Health/Div. of Health Care Financing Staff Present:

Lisa V Hunt, R.Ph.
 Trevor Smith C.Ph.T.
 Merelynn Berrett, R.N.

Tim Morley, R.Ph.
 Richard Sorenson, R.N.

Other Individuals Present:

Charissa Anne, J&J
 John Madigan, J&J
 Kim Eggert, Gilead
 Raza Karim, Abbvie
 Mike Broadhead, Abbvie
 Lisa Jenson, Gilead
 Travis Bastow, UofU
 Gary Oderda, UofU
 Scott Larson, BMS

Laura Litzenburger, J&J
 Joanita Lake, UofU
 Michele Puyear, Gilead
 Don McCaffrey, Vertex
 John Vu, Molina
 Bryan Larson, UofU
 Scott Clegg, Lilly
 Chris Desimone, Aegerion
 Cody Ball, Select Health

Meeting conducted by: Tony Dalpiaz, Pharm.D.

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Lisa Hunt welcomed everyone to the meeting and reminded everyone to sign in.
3. **P&T Committee report** – Lisa Hunt addressed the board she reported that new classes have been added to the Preferred Drug List on July 1st.
4. **Approval of prior meeting minutes** – Michael Symond made a motion to approve the May minutes. Keith Tolman seconded the motion. All others in favor.

5. **Hepatitis C (Sovaldi & Olysio)** – Lisa Hunt presented some additional guidelines about the new Hepatitis C products. Also presented was PA criteria used in other States, and criteria used by the Utah Medicaid Accountable Care Organizations (ACOs). She presented updated usage of the different Hepatitis C drugs as well.
6. Keith Tolman presented a detailed history of Hepatitis C and information about treatment options. He spoke about the disadvantages the population who are affected by Hepatitis C who are often poor, IV drug users. He said that the newer drugs are without the harsh side effects of previous generation drugs. Dr Tolman said that because these drugs are so expensive, it is important and a challenge to ensure they are distributed in an effective manner. The virus has many genotypes that some medications are not effective at treating.
7. **Public Comment**
 - a. **Michelle Puyear (Gilead, Sovaldi)** – Offered to answer any questions from the board.
 - b. **Laura Litzenburger (Jansen, Olysio)** – Answered questions from board members.
8. **Board Discussion**
 - a. Jennifer Brinton said that she thinks a PA on the drugs is helpful because of the specific genotypes needed for drug therapy.
 - b. Michael Symond said that he feels better having requirements to ensure correct usage, especially for providers who do not work extensively with this disease.
 - c. Keith Tolman said that a new program may start to allow providers to work with experts in specific fields via web conference. This could help with providers in rural areas, or for providers who may not be experts in the specific area.
 - d. Susan Siegfried said that at the Veterans Affairs hospital, Hepatitis C patients would test for viral load and genotype prior to treatment.
 - e. Lisa Hunt asked about the draft criteria for Sovaldi and Olysio to see if the board wants to change any of the criteria. She asked if there should be specialist requirement on the PA forms.
 - f. Michael Symond said that having access to good information about the best prescribing practices for these drugs that are not commonly used is very important. He said that it is much quicker to talk to a person directly than to use an online search engine.
 - g. Lisa Hunt said that Utah Medicaid can put links to resources on the PA form so the provider can automatically find the most up to date guidelines for prescribing.
 - h. Keith Tolman said that there isn't a need for this to be restricted to a specialists. He then said that it would be nice to have an online PA system to speed through the submission process, and know the criteria.
 - i. Lisa Hunt said that eportal on the Utah Medicaid website is already available and prescribers can submit the PA online already.
 - j. Michael Symond said that including the links to professional guidelines for prescribing would be very valuable.
 - k. Lisa Hunt restated that criteria on the draft PA sheets provided.
 - l. Keith Tolman said that one thing that would be good is to remove the requirement

to treat with a ribavirin agent, as the new COSMOS study that is set to be approved will not recommend this route.

- m. Keith Tolman and Susan Siegfried both commented that the viral load criteria is not needed to be apart of the form.
- n. Tony Dalpiaz added that on the Olysio criteria sheet, that the NS3 Q80K polymorphism testing on genotype 1a is only required if the drug is used in combination with interferon and suggested that this should be added to the criteria sheet.
- o. Jennifer Brinton and made a motion to use the criteria draft that was presented with the changes mentioned by the board of eliminating the requirement of using ribavirin and to remove the requirement for viral load testing on both the Olysio and Sovaldi criteria sheets. Included with the motion was to include on the Olysio criteria sheet the NS3 Q80K polymorphism testing on genotype 1a is only required if the drug is used in combination with interferon. Also included in the motion is that the criteria sheets will include links to the most up to date guidelines for prescribing the drugs and that the criteria be subject to change as the guidelines evolve and change with new developments. Kyle Jones seconds the motion. All board members in favor.

9. Meeting Adjourned – No DUR petitions

The next DUR Board meeting is scheduled for Thursday, August 14, topics include proton pump inhibitors, stimulants for children review, clonidine review, topical immunomodulator agents, antidiarrheal agent (Fulyzaq).

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov